DCTH at a glance
DELCATH SYSTEMS, INC. (DCTH, SEC CIK 872912) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as May 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), DELCATH SYSTEMS, INC. (DCTH) reported revenue of $85.2 million (up 129.1% from FY2024) and net income of $2.7 million. Diluted EPS was $0.07.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding DELCATH SYSTEMS, INC. (DCTH) shares worth $88.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Pennell Sandra on March 6, 2026 of 5,533 shares at $9.04 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $85.2M
- +129.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $88.3M · +2 vs prior quarter
- Latest 8-K
- Aug 14, 2026
- Item 5.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes in risk factors from the Annual Report
- Carried-forward risk: unknown or currently immaterial risks could materially impair results
- Regulatory compliance risk: applicable securities laws govern the $25 million share repurchase program
- Liquidity risk: approximately $16.0 million remained available for repurchases as of June 30, 2026
- Market risk: repurchase timing depends on market conditions, liquidity, and financial condition
AI summary of the DCTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Bylaws amended August 12, 2026, effective immediately, by board action
- Delaware Chancery Court designated exclusive forum for internal corporate claims
Item EX-99.1: Item EX-99.1
- Q2 revenue rose to $29.1M from $24.2M, led by HEPZATO KIT revenue of $27.1M
- Gross margin expanded to 90% from 86%, supporting strong product economics
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references a press release, but the provided text contains no operating or financial results
- Disclosure is furnished, not filed, limiting Section 18 liability and incorporation into future SEC filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 1,800,000 additional common shares for Delcath’s 2020 Omnibus Equity Incentive Plan
- Expanded equity pool increases capacity for employee, executive, and director compensation
Item 5.07: Submission of Matters to a Vote of Security Holders
- 67.44% shareholder participation, with 23,346,271 of 34,618,159 eligible shares represented
- Elizabeth Czerepak and John R. Sylvester elected as Class II directors through the 2029 Annual Meeting
AI summaries of DCTH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DCTH
Don't miss the next DCTH filing
- Alerts as it files. A push when DCTH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DCTH, by share count.
- Ask anything. An AI agent that reads every DCTH filing and answers with sources.
DCTH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Aharon Gil | A | May 13, 2026 | 22,500 | - |
| Martell Bridget A | A | May 13, 2026 | 22,500 | - |
| SALAMON STEVEN A J | A | May 13, 2026 | 22,500 | - |
| CZEREPAK ELIZABETH | A | May 13, 2026 | 22,500 | - |
| Aharon Gil | A | May 13, 2026 | 22,500 | - |
| Sylvester John Richard | A | May 13, 2026 | 22,500 | - |
| Sylvester John Richard | A | May 13, 2026 | 22,500 | - |
| CZEREPAK ELIZABETH | A | May 13, 2026 | 22,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $37.2M | $85.2M |
| Gross Profit | - | $31.0M | $73.4M |
| Operating Income | - | -$12.4M | $660K |
| Net Income | - | -$26.4M | $2.7M |
| Gross Margin | - | 83.4% | 86.2% |
| Op. Margin | - | -33.4% | 0.8% |
| Net Margin | - | -70.9% | 3.2% |
| Balance Sheet | |||
| Total Assets | $38.6M | $76.6M | $123.6M |
| Equity | - | $68.7M | $111.2M |
| ROE | - | -38.4% | 2.4% |
| Per Share | |||
| EPS | - | $-0.93 | $0.07 |
| Cash Flow | |||
| Operating CF | - | -$18.7M | $22.5M |
| CapEx | $58K | $559K | $1.5M |
Source: XBRL data in DELCATH SYSTEMS, INC. (DCTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DCTH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $88.3M |
| Q1 2026 | 21 | $55.5M |
| Q4 2025 | 19 | $66.9M |
| Q3 2025 | 21 | $68.1M |
| Q2 2025 | 21 | $93.6M |
| Q1 2025 | 13 | $44.4M |
| Q4 2024 | 9 | $28.3M |
| Q3 2024 | 8 | $9.1M |
- BlackRock+922.3K (+52%)
- AQR Capital Management+140.9K (+439%)
- Morgan Stanley+22.5K (+6%)
- Wells Fargo & Co+17.1K (+153%)
- Vanguard Portfolio Management LLC+15.4K (+9%)
- Vanguard Capital Management LLC−108.0K (-8%)
- Citadel Advisors LLC−62.2K (-81%)
- Goldman Sachs Group−38.8K (-13%)
- Millennium Management−21.7K (-4%)
- JPMorgan Chase & Co−237 (-2%)
- Dimensional Fund Advisors+210.3K
- D.E. Shaw & Co+57.9K
- Two Sigma Investments+10.1K
- U.S. Bancorp+104
- Renaissance Technologies LLC−155.3K
- Ameriprise Financial−22.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 135 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DCTH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 28, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Mar 20, 2026 | - | - | |
| 4 | Mar 6, 2026 | - | - | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Mar 3, 2026 | - | - | - |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 18, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 4 | Nov 25, 2025 | - | - | |
| 10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
| SC 13G | Oct 17, 2025 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
DCTH SEC filings: frequently asked questions
Which institutions hold DCTH stock?
As of June 30, 2026, the largest DELCATH SYSTEMS, INC. (DCTH) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), Vanguard Capital Management LLC ($15.4 million), State Street Corp ($8.6 million), Millennium Management ($7.1 million), Morgan Stanley ($5.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DCTH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), DELCATH SYSTEMS, INC. (DCTH) reported revenue of $85.2 million (up 129.1% from FY2024) and net income of $2.7 million. Diluted EPS was $0.07. The figures come from the XBRL data in the 10-K.
What did DCTH report in its latest 8-K?
DELCATH SYSTEMS, INC. (DCTH) filed an 8-K on August 14, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Bylaws amended August 12, 2026, effective immediately, by board action.
What are the latest DCTH SEC filings?
DELCATH SYSTEMS, INC. (DCTH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on May 14, 2026.
What is DCTH's SEC CIK number?
DELCATH SYSTEMS, INC. (DCTH)'s SEC Central Index Key (CIK) is 872912. EDGAR lists every DCTH filing under that number.
Ask anything about DCTH
The research agent reads DCTH's filings, financials, insider trades and 13F holders, then answers with sources.